Companies Investors People

Drop to look up

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

Contact
Request a Demo
Request Data Updates
Add a Company

Research

Companies
Investors
People

aVenture

Download App
Pricing
Alternatives

For iPhone and iPad

Resources

Documentation
Use Cases
CLI
MCP
Sitemap

aVenture is an AI-native agentic deep research tool for researching and finding companies and people, and is a high-quality alternative to AlphaSense, CB Insights, Crunchbase, Dealroom, Harmonic, Owler, Perplexity Finance, PitchBook, Preqin, PrivCo, Synaptic, and Tracxn.

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Terms of service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Tourmaline Bio

Tourmaline Bio

Tourmaline Bio is a late-stage clinical biotechnology company whose lead program is TOUR006, a naturally long-half-life anti-IL-6 antibody.

: Acquired, subsidiary of Novartis
: 2021
: New York, NY, USUnited States

Tourmaline Bio is a late-stage clinical biotechnology company advancing its lead program, TOUR006, an anti-IL-6 antibody with a naturally long half-life, for thyroid eye disease and atherosclerotic cardiovascular disease. Tourmaline Bio is developing TOUR006 in diseases characterized by inflammation and autoantibodies, an area where IL-6 pathway inhibitors have been underexplored.

Tourmaline Bio is developing a drug for patients at residual inflammatory risk in ASCVD, with subcutaneous dosing once every three months. Cholesterol-lowering drugs can manage the condition, but many, including widely prescribed statins, are daily pills. No widely adopted anti-inflammatory therapies are currently available for cardiovascular risk reduction.

M & A Snapshot

Novartis
Acquired Tourmaline Bio Oct 28, 2025 for $1.4B

Similar Companies

Korsana Biosciences

Anew Labs

Alzheon

ORIC Pharmaceuticals

Inhibrx Biosciences

Eton Pharmaceuticals

Marksans Pharma

Ocular Therapeutix

Idorsia

Freenome

Everest Medicines

Lotus Pharmaceutical

Grupo Cimed

D&D Pharmatech

Tyra Biosciences

Moonlight Therapeutics

Novartis

Torl Biotherapeutics

torlbio.com

Narval

narvalbio.com

Upstream Bio

upstreambio.com

Quick Facts

Who are Tourmaline Bio's competitors?

Companies similar to Tourmaline Bio include Korsana Biosciences, Anew Labs, Alzheon and ORIC Pharmaceuticals.

When was Tourmaline Bio founded?

Tourmaline Bio was founded in 2021.

Where is Tourmaline Bio's headquarters located?

Tourmaline Bio's headquarters is located in New York, NY, US.

How much disclosed funding has Tourmaline Bio raised?

As of the latest available date, Tourmaline Bio has disclosed funding of $112M (USD). Undisclosed round amounts are excluded.

Classification

Industry: Biopharmaceuticals
Biotech
Technology: Antibody Engineering
Geographic Exposure: United States

Model: Clinical Stage Biopharma
Revenue: Licensing
Customer: B2B

Tags: Biotech
Therapeutics